Cargando…

Management of potential drug-drug interactions with nirmatrelvir-ritonavir and oral anticoagulants: a case series

Detalles Bibliográficos
Autores principales:	Vazquez, Sara R., Wilson, Aaron S., Witt, Daniel M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579540/ https://www.ncbi.nlm.nih.gov/pubmed/36253637 http://dx.doi.org/10.1007/s11239-022-02707-4

Ejemplares similares

Drug Interactions With Nirmatrelvir-Ritonavir in Older Adults Using Multiple Medications
por: Ross, Sydney B., et al.
Publicado: (2022)

Tacrolimus Drug–Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin
por: Sindelar, Morganne, et al.
Publicado: (2022)

Comment on “Tacrolimus Drug-Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin”
por: de Oliveira, Luciana Mello, et al.
Publicado: (2023)

Nirmatrelvir/ritonavir as a possible treatment for Long-COVID
por: Catalán, Ignacio Pérez, et al.
Publicado: (2023)

Response to Comment on “Tacrolimus Drug-Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin”
por: Sindelar, Morganne, et al.
Publicado: (2023)

Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications
por: Marzolini, Catia, et al.
Publicado: (2022)

COVID-19 “Rebound” associated with nirmatrelvir/ritonavir pre-hospital therapy
por: Coulson, J.M., et al.
Publicado: (2022)

Minimal Risk of Drug-Induced Liver Injury With Molnupiravir and Ritonavir-Boosted Nirmatrelvir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2023)

Virological and clinical rebounds of COVID-19 soon after nirmatrelvir/ritonavir discontinuation
por: Antonelli, Guido, et al.
Publicado: (2022)

Post-acute hospitalization and mortality of nirmatrelvir plus ritonavir for COVID-19 survivors
por: Hsu, Wan-Hsuan, et al.
Publicado: (2023)

Clinical effectiveness of nirmatrelvir plus ritonavir in the treatment of COVID-19 for patients with dementia
por: Liu, Ting-Hui, et al.
Publicado: (2023)

Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19
por: Gao, Yuan, et al.
Publicado: (2023)

Nirmatrelvir/ritonavir as a potential treatment for prolonged SARS-CoV-2 infection in immunocompromised patients
por: Catalán, Ignacio Pérez, et al.
Publicado: (2022)

Drug Interactions With a Short Course of Nirmatrelvir and Ritonavir: Prescribers and Patients Beware
por: Ratain, Mark J., et al.
Publicado: (2022)

Benefits of nirmatrelvir–ritonavir remain unproven for some populations
por: McDonald, Emily G., et al.
Publicado: (2022)

Molnupiravir and nirmatrelvir–ritonavir reduce mortality risk during post-acute COVID-19 phase()
por: Wan, Eric Yuk Fai, et al.
Publicado: (2023)

Drug Interaction Between Tacrolimus and Paxlovid (Nirmatrelvir/Ritonavir) in an Adolescent with Inflammatory Bowel Disease
por: Zaarur, Leenoy, et al.
Publicado: (2023)

Nirmatrelvir-ritonavir for COVID-19
por: McDonald, Emily G, et al.
Publicado: (2022)

Nirmatrelvir and ritonavir for COVID-19
Publicado: (2022)

Cardiovascular Drug Interactions With Nirmatrelvir/Ritonavir in Patients With COVID-19: JACC Review Topic of the Week
por: Abraham, Sonu, et al.
Publicado: (2022)

Generalized use of Nirmatrelvir plus ritonavir (Paxlovid): Raising concerns
por: Sánchez Fabra, David, et al.
Publicado: (2023)

Generalized use of Nirmatrelvir plus ritonavir (Paxlovid): Raising concerns
por: Sánchez Fabra, David, et al.
Publicado: (2023)

Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT)
por: Lemaitre, Florian, et al.
Publicado: (2022)

Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
por: Hung, Yuan-Pin, et al.
Publicado: (2022)

Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19
por: Girardin, François, et al.
Publicado: (2022)

Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer
por: Anwar, Kaleem, et al.
Publicado: (2022)

Immunologic characterization of a patient with clinical and virologic rebound upon Nirmatrelvir/Ritonavir treatment: the unfortunate epilogue of COVID-19
por: Marchetti, Giulia, et al.
Publicado: (2023)

Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022)

Successful use of nirmatrelvir/ritonavir in immunocompromised patients with persistent and/or relapsing COVID-19
por: Graziani, Lucia, et al.
Publicado: (2022)

VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19
por: Cao, Zhujun, et al.
Publicado: (2022)

Nirmatrelvir/ritonavir use in patients with COVID-19 on hemodialysis: a case series
por: Zhang, Ai-hua, et al.
Publicado: (2023)

Possible medication error risks with nirmatrelvir+ritonavir
Publicado: (2022)

Correction to: Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022)

Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
por: Lu, Jiayue, et al.
Publicado: (2023)

Impact of extended-course oral nirmatrelvir/ritonavir (Paxlovid) in established Long COVID: Case series and research considerations
por: Cohen, Alison K., et al.
Publicado: (2023)

COVID-19 and antiepileptic drugs: an approach to guide practices when nirmatrelvir/ritonavir is co-prescribed
por: Yalcin, Nadir, et al.
Publicado: (2022)

Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir
por: Akinosoglou, Karolina, et al.
Publicado: (2022)

Association nirmatrelvir/ritonavir contre la COVID-19
por: McDonald, Emily G., et al.
Publicado: (2022)

Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19
por: Anderson, Annaliesa S., et al.
Publicado: (2022)

Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19
por: Reis, Stefanie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_24bbkjqf7gt12hejanppj81mhu